As filed with the Securities and Exchange Commission on March 30, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
FORMA THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 37-1657129 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
500 Arsenal Street, Suite 100
Watertown, MA 02472
(617) 679-1970
(Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)
Forma Therapeutics Holdings, Inc. 2020 Stock Option and Incentive Plan
Forma Therapeutics Holdings, Inc. 2020 Employee Stock Purchase Plan
(Full title of the plans)
Frank D. Lee
President and Chief Executive Officer
500 Arsenal Street, Suite 100
Watertown, MA 02472
(617) 679-1970
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| ||||||||
| Title of securities to be registered | Amount to be registered(1) | Proposed maximum offering price per share | Proposed maximum aggregate offering price | Amount of registration fee(6) | ||||
Common Stock, $0.001 par value per share | 1,892,009 (2) | $25.93 (3) | $49,059,793.37 | $5,352.43 | ||||
Common Stock, $0.001 par value per share | 472,487 (4) | $22.04 (5) | $10,413,613.48 | $1,136.13 | ||||
Total | 2,364,496 | $59,473,406.85 | $6,488.56 | |||||
| ||||||||
| ||||||||
| (1) | In accordance with Rule 416(a) under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. |
| (2) | Consists of 1,892,009 additional shares issuable under the 2020 Stock Option and Incentive Plan (the “2020 Plan”), which represents the automatic annual increase to the number of shares available for issuance under the 2020 Plan effective as of January 1, 2021. Shares available for issuance under the 2020 Plan were previously registered on registration statement on Form S-8 filed with the Securities and Exchange Commission on June 23, 2020 (File No. 333-239369). |
| (3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of $25.93, the average of the high and low price of the registrant’s Common Stock as reported on the Nasdaq Global Market on March 26, 2021. |
| (4) | Consists of 472,487 additional shares issuable under the 2020 Employee Stock Purchase Plan (the “2020 ESPP”), which represents the automatic annual increase to the number of shares available for issuance under the 2020 ESPP effective as of January 1, 2021. Shares available for issuance under the 2020 ESPP were previously registered on registration statement on Form S-8 filed with the Securities and Exchange Commission on June 23, 2020 (File No. 333-239369). |
| (5) | The price of $22.04 per share, which is 85% of the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Global Market on March 26, 2021, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act of 1933, as amended, and has been used as these shares are without a fixed price. Pursuant to the 2020 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the fair market value of a share of Common Stock on the first trading day of the offering period or on the exercise date, whichever is less. |
| (6) | Calculated pursuant to Section 6(b) of the Securities Act of 1933, as amended. |
STATEMENT OF INCORPORATION BY REFERENCE
This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 1,892,009 shares of the Registrant’s common stock, $0.001 par value per share, to be issued under the Registrant’s 2020 Stock Option and Incentive Plan and (ii) an additional 472,487 shares of the Registrant’s common stock, $0.001 par value per share, to be issued under the Registrant’s 2020 Employee Stock Purchase Plan. This Registration Statement incorporates by reference the contents of the registration statement on Form S-8, File No. 333-239369, filed by the Registrant on June 23, 2020, relating to the Registrant’s 2020 Stock Option and Incentive Plan and 2020 Employee Stock Purchase Plan pursuant to General Instruction E.
Part II
| Item 8. | Exhibits. |
The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
EXHIBIT INDEX
| * | Filed herewith. |
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on this 30th day of March, 2021.
| FORMA THERAPEUTICS HOLDINGS, INC. | ||
| By: | /s/ Frank D. Lee | |
| Name: Frank D. Lee | ||
| Title: President, Chief Executive Officer and Director | ||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Frank D. Lee, Todd Shegog and Jeannette Potts, Ph.D., J.D. as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.
| Name | Title | Date | ||
/s/ Frank D. Lee | President, Chief Executive Officer and Director (Principal Executive Officer) | March 30, 2021 | ||
| Frank D. Lee | ||||
/s/ Todd Shegog | Chief Financial Officer (Principal Financial Officer and | March 30, 2021 | ||
| Todd Shegog | ||||
/s/ Timothy P. Clackson | Director | March 30, 2021 | ||
| Timothy P. Clackson, Ph.D. | ||||
/s/ Marsha Fanucci | Director | March 30, 2021 | ||
| Marsha Fanucci | ||||
/s/ Wayne A.I. Frederick, M.D. | Director | March 30, 2021 | ||
| Wayne A.I. Frederick, M.D. | ||||
/s/ Peter Kolchinsky | Director | March 30, 2021 | ||
| Peter Kolchinsky, Ph.D. | ||||
/s/ Paolo Paoletti | Director | March 30, 2021 | ||
| Paolo Paoletti, M.D. | ||||
/s/ Selwyn M. Vickers, M.D. | Director | March 30, 2021 | ||
| Selwyn M. Vickers, M.D. | ||||
/s/ Thomas G. Wiggans | Director | March 30, 2021 | ||
| Thomas G. Wiggans | ||||
/s/ Peter J. Wirth | Director | March 30, 2021 | ||
| Peter J. Wirth, J.D. | ||||
